Webinars
Watch our latest webinars below, or view webinars from previous years.
Improving Diversity in Clinical Trials for Hepatitis B Treatments
This session discusses why representation, including of persons living with hepatitis B, is essential to research, and communication and outreach strategies to improve diversity in clinical trials. Christine Lee, PharmD, PhD, from the U.S. Food & Drug Administration (FDA) provides an overview of clinical trials recruitment and strategies to improve participation and Rhea Racho, MPAff, discusses the Hepatitis B Foundation's participation in the National Institute of Health's All of Us Research Program and how the program is working to make medical research more inclusive.
Presentation Slides:
FDA Office of Minority Health and Health Equity; Christine Lee
All of Us Research Program; Rhea Racho
Resources:
HBF Clinical Trials Finder
HBV Drug Watch
Innovative Outreach Strategies for Hepatitis B: Lessons from HBU Grantees
Hepatitis B experts and past Hep B United mini-grant recipients around the country share innovative approaches to hepatitis B outreach. Three expert panelists from the Immunize Colorado, Korean Community Services in New York, and Midwest Asian Health Association from Chicago will report on strategies for hard to reach populations and hepatitis B.
Presentation Slides:
Immunize Colorado; Kristin Mlynarczyk
KCS Hep B Outreach: Reaching Faith Leaders and Patients in the Korean Community; Paul Lee
Hepatitis B Mentorship Program for Bangladeshi Community in Michigan; Hong Liu
Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies?
Hepatitis delta expert, Dr. Ohad Etzion, outlines the challenges in controlling the disease, current clinical trials, and explores ideal endpoints for treatment and control of hepatitis B and delta co-infection.
Presentation Slides:
Hepatitis D Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies?
Improving Access to Hepatitis B Treatments
Panelists discuss research findings of hepatitis B treatments offered by health plans, resources for prescription assistance, and provide an overview of and opportunities to get involved in federal and state legislative advocacy efforts to combat discriminatory practices by health insurers.
Presentation Slides:
Adverse Drug Tiering Practices in the United States; Michaela Jackson
Co-Pay Accumulators: What Patients Need to Know in 2020; Rachel Klein
Hepatitis B Testing and Vaccination Programs in Correctional Facilities
Incarcerated persons often have a disproportionate burden of infectious diseases, including hepatitis B infection. The Advisory Committee on Immunization Practices (ACIP) recommends universal hepatitis B vaccination of adults in high-risk settings including correctional facilities. In this webinar, panelists share efforts to increase hepatitis B testing and vaccination in state jails and prisons in Maine, Oregon, and Tennessee.
Presentation Slides:
Viral Hepatitis Vaccination Program in County Jails - Tennessee; Rebecca Lakey
Hepatitis B and Incarceration in Maine; Jeff Caulfield
Public Health in Prison - the Oregon Experience; Ann Chakwin
National and State Initiatives to Prevent Hepatitis B and Liver Cancer
October is Liver Cancer Awareness Month! Did you know that in the U.S., the rates of liver cancer incidence and deaths are increasing while most other cancer rates have declined or stabilized? Panelists discuss liver cancer and its risk factors, the Centers for Disease Control and Prevention (CDC) National Comprehensive Cancer Control Program, and promising state-based initiatives and strategies for liver cancer prevention, including hepatitis B vaccination awareness and provider education activities.
Presentation Slides:
CDC National Comprehensive Cancer Control Program and Idaho Department of Health and Welfare Program; Behnoosh Momin and Charlene Cariou
Jacki's Story; Jacki Chen
Resources:
Jacki - #justB Treated Video
CDC Cancer Survivors Resource Center
Idaho Cancer Control and Prevention Program Video PSA: Prevent Hepatitis B
A Global Scientific Strategy to Cure Hepatitis B
HBV is a global public health challenge on the same scale as tuberculosis, HIV, and malaria. More than 257 million people worldwide are chronically infected with HBV and nearly 900,000 people died from the disease in 2017. During this session, panelists discuss International Coalition to Eliminate HBV (ICE-HBV) and how a global scientific strategy lays the groundwork for the momentum behind hepatitis B cure research and the long-term implementation of HBV cure preparedness worldwide.
Presentation Slides:
HBV Cure Science 101; John Tavis
A Global Approach to Curing Chronic Hepatitis B: ICE-HBV; T. Jake Liang
Patient Perspective: ICE-HBV Cure Strategy; Joan Block
Handouts:
ICE-HBV Brochure
ICE-HBV Media Release
Article: A Global Scientific Strategy to Cure HBV
HBF Roadmap for a Cure
Hidden Consequences: the Opioid Epidemic and Rising Hepatitis B Rates
Hep B United and the National Association of County and City Health Officials (NACCHO) are excited to present a 3-part webinar series on local strategies to eliminate hepatitis B. In this final installment, panelists explore the rising rates of acute hepatitis B infection across the U.S., discuss the impact of the opioid epidemic on increasing hepatitis infection rates, share local initiatives and challenges in addressing the epidemic, and identify best practices, tools, and other resources helpful to addressing hepatitis B in local communities.
Presentation Slides:
Alphabet Study: A, B, C, D; Jack Hildick-Smith
LENOWISCO Health District Comprehensive Harm Reduction Program; Michelle McPheron
Handouts:
Community Response Planning for Outbreaks of Hepatitis and HIV Among People Who Inject Drugs: A Case Study from LENOWISCO Health District, A Rural Community in Virginia
Exploring National and Local Approaches to Perinatal Hepatitis B Prevention
Hep B United and the National Association of County and City Health Officials (NACCHO) are excited to present a 3-part webinar series on local strategies to eliminate hepatitis B. To coincide with National Infant Immunization Week (April 27 – May 4) and Hepatitis Awareness Month (May), this session focuses on perinatal HBV transmission. Learn more about the importance of the national Perinatal Hepatitis B Prevention Program, as well as hear from a local health department that NACCHO has recognized for its innovative strategies to prevent perinatal HBV transmission.
Presentation Slides:
Perinatal Hepatitis B; Noele Nelson (CDC)
Innovative Strategy to Increase Identification of Infants Born to Chronic Hepatitis B Mothers; Essi Havor (Houston Health Department)
Webinar Q&A Session
Handouts:
CDC Fact Sheet: When a Pregnant Woman has Hepatitis B
CDC Fact Sheet: Hepatitis B and Your Baby
CDC Infographic: Vaccinate Your Baby Against Hepatitis B
City of Houston Health Dept. Perinatal Hepatitis B Assessment Notification Letter
City of Houston Health Dept. Hepatitis B Chart Review Info & Instructions for Hospitals
Houston Health Dept. Perinatal Hepatitis B Policy & Practices Survey
The Landscape of Hepatitis B in the United States
Hep B United and the National Association of County and City Health Officials (NACCHO) are excited to present a 3-part webinar series on local strategies to eliminate hepatitis B. This session focuses on the current state of hepatitis B in the U.S. Learn about hepatitis B epidemics across the nation, communities at high risk for infection, and HBV routes of transmission, test results , case reporting, vaccines, and local health department prevention initiatives.
Presentation Slides:
The Landscape of Hepatitis B in the U.S.; Sierra Pellechio (HBF) and Michelle Cantu (NACCHO)
Handouts:
Local Approaches to Preventing Eliminating Hepatitis B Webinar Series
NACCHO HBV Vaccination Toolkit
About the Hepatitis B Foundation
Hep B United Overview and Local Members
Hep B Fast Facts
Fact Sheet: Understanding Your HBV Blood Tests
Hepatitis B: Dispelling Myths and Misconceptions
How is hepatitis B spread? If I am infected, can I breastfeed my baby? What is the hepatitis B vaccine schedule? Our expert panelists discuss common myths about hepatitis B prevention and transmission and how to address common misconceptions.
Presentation Slides:
Hepatitis B: Dispelling Myths and Misconceptions; Maureen Kamischke, Ponni Perumalswami, and Amy Tang
Epidemiological Tools and Analytics to Support the Global Elimination of Hepatitis B
Devin Razavi-Shearer, HBV/HDV Project Lead at the Center for Disease Analysis Foundation, provides an overview of models to expand hepatitis B data through the Polaris Observatory and resources to increase access to hepatitis B screening and treatment.
Presentation Slides:
Epidemiological Tools and Analytics to Support the Global Elimination of Hepatitis B; Devin Razavi-Shearer
Handouts:
Center for Disease Analysis Foundation Brief
Polaris Observatory Brief
Hepatitis Delta: Current and Future Treatments
Professor Cihan Yurdaydin, MD, secretary general for the World Gastroenterology Organization and Educational Councilor of EASL, provides an in-depth perspective on current treatment regimens for hepatitis delta and a look at new drugs in the pipeline that show promise for more effective future treatments.
Presentation Slides:
Hepatitis Delta - Current and Future Treatments; Cihan Yurdaydin